SEC Form 4 · accession 0001209191-15-053913
Evofem Biosciences, Inc. · EVFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Kemmerer
Officer — VP, Pharma Dev & Manufacturing
Period of report
Jun 12, 2015
Accepted (ET)
Jun 16, 2015 · 5:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618835
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 12, 2015 | M | 10,848 | $1.22 | A | 10,848 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock (Right to Buy)F1 | $1.22 | Jun 12, 2015 | M | 10,848 | D | — | Apr 22, 2018 | Common Stock | 10,848 | 0 | D |
Explanation of responses
- F125% of the option shares vest on April 14, 2009 and the remaining option shares will vest in 36 equal monthly installments theafter.